JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced 38 scientific abstracts across five difficult-to-treat disorders of the central nervous system will be presented at the 70th Annual Meeting of the American Academy of Neurology (AAN) in Los Angeles from April 21-27, 2018. The breadth of data spans a diverse set of patient populations including migraine, multiple sclerosis, tardive dyskinesia and Huntington’s disease.
“Teva’s data at AAN embodies our expertise in researching and developing highly complex treatments for CNS disorders, especially those for which there is still an enormous unmet patient need,” said Tushar Shah, M.D., Senior Vice President, Head of Specialty Clinical Development and Medical Affairs at Teva. “Our ongoing research reflects Teva’s goal of developing innovative therapeutic solutions that aim to help enable people to live better days.”
Among the 21 accepted migraine abstracts to be presented, 19 include additional data from the Phase III HALO clinical trial program for fremanezumab, a monoclonal antibody targeting the CGRP (calcitonin gene-related peptide) ligand, currently being investigated as a preventive treatment for migraine. These data examined the overall efficacy, safety and tolerability profile of fremanezumab in both chronic and episodic migraine. Studies included patients on fremanezumab alone or in combination with other preventive medications.
Additional data further contribute to the scientific understanding of the efficacy, safety and tolerability of Teva’s COPAXONE® (glatiramer acetate injection) for the treatment of relapsing multiple sclerosis (RMS), including up to seven-year results from the Glatiramer Acetate Low-Frequency Administration (GALA) study and an abstract assessing pregnancy outcomes in RMS patients exposed to COPAXONE® 20 mg/mL during all three trimesters. Teva will also present AUSTEDO® (deutetrabenazine) tablets data providing clinical and real-world insights into the applicability of use across chorea associated with Huntington’s disease and tardive dyskinesia in adults, two often underserved and overlooked movement disorders.
The full set of Teva-sponsored data to be presented includes:
- [S32.005] Efficacy of Two Dose Regimens of Subcutaneous Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine (Platform Session 32, April 25, 2018, 1:00 - 3:00 p.m. PT)
- [S32.007] The Impact of Fremanezumab on Work Productivity and Activity Impairment in Patients with Chronic Migraine (Platform Session 32, April 25, 2018, 1:00 - 3:00 p.m. PT)
- [P3.139] The Impact of Headache Free Days on Quality of Life and Costs Among People with Migraine with >4 Headache Days in the Past Month (Poster Session 3, April 24, 2018, 11:30 - 7:00 p.m. PT)
- [P3.144] Burden of Illness Among Treated Migraine Patients with ≥4 Headache Days in the Past Month (Poster Session 3, April 24, 2018, 11:30 - 7:00 p.m. PT)
- [P4.093] Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.095] The Impact of Fremanezumab on Headache-Related Disability in Patients with Episodic Migraine using the Migraine Disability Assessment (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.097] Efficacy of Fremanezumab in Patients With Chronic Migraine and Comorbid Moderate to Moderately Severe Depression (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.099] Efficacy of Fremanezumab in Patients With Chronic Migraine With or Without Concomitant Use of Preventive Medication (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.101] Impact of Fremanezumab on the Number of Days with Use of Acute Headache Medications in Chronic Migraine (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.102] Onset of Action with Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.104] Efficacy of Fremanezumab in Patients With Chronic Migraine Who Had Prior Use of Topiramate or OnabotulinumtoxinA (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.106] Impact of Fremanezumab on the Number of Days With Use of Acute Headache Medications in Episodic Migraine (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.107] Onset of Action with Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.109] The Impact of Fremanezumab on Headache-Related Disability in Patients with Chronic Migraine Using the Headache Impact Test (HIT-6) (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.110] Efficacy of Fremanezumab in Patients With Episodic Migraine Who Had Prior Use of Topiramate or OnabotulinumtoxinA (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.111] Fremanezumab for Decreasing Migraine Symptoms such as Nausea, Vomiting, Photophobia and Phonophobia and Reducing the Need for Acute Medications in the First Week of Treatment in the HFEM Study (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.112] Reversion of Patients With Chronic Migraine to an Episodic Migraine Classification With Fremanezumab Treatment (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.113] Response with Fremanezumab in the Treatment of Chronic Migraine (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.114] Fremanezumab for Reducing Headache Pain within the First Week of Beginning Treatment in the Phase 2 Episodic Migraine Study (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.115] The Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Episodic Migraine (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.117] The Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life and Overall Health Status in Chronic Migraine (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P1.370] Integrated Transcriptomic and Physicochemical Characterization of Glatiramer Acetate Products (Copaxone and Glatopa) Available in the United States (Poster Session 1, April 22, 2018, 11:30 - 5:30 p.m. PT)
- [P1.400] Physicochemical and Biological Characterization of both Copaxone and the European Follow-On Glatiramer Acetate Product (Poster Session 1, April 22, 2018, 11:30 - 5:30 p.m. PT)
- [P3.415] Defining Glatiramer Acetate: The USA Definition of Sameness and the EU Definition of Similarity (Poster Session 3, April 24, 2018, 11:30 - 7:00 p.m. PT)
- [P3.416] Bayesian Analysis of Glatiramer Acetate 40 mg/mL TIW Treatment Effect in Reducing Relapse Rate (Poster Session 3, April 24, 2018, 11:30 - 7:00 p.m. PT)
- [P4.362] Pregnancy Outcomes in Patients with Multiple Sclerosis and Exposure to Branded Glatiramer Acetate During all Three Trimesters (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P6.378] Long-term Efficacy, Safety, and Tolerability of Three-times Weekly Dosing Regimen of Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis Patients: 5-year Results of the Glatiramer Acetate Low-Frequency Administration (GALA) Open-label Extension Study (Poster Session 6, April 27, 2018, 11:30 - 5:30 p.m. PT)
- [P4.040] Initial Deutetrabenazine Compliance, Satisfaction, and Patient Perception of Change in Huntington Disease Symptoms (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.044] Healthcare Utilization and Costs for Huntington Disease Patients Prescribed Tetrabenazine (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.050] Experience of Individuals With Huntington Disease and Chorea (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.075] Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-Label Extension Study (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.076] Long-Term Treatment With Deutetrabenazine is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.077] Effect of Tardive Dyskinesia on Quality of Life: Patient-reported Symptom Severity is Associated with Deficits in Physical, Mental, and Social Functioning (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.080] Cardiovascular Safety Assessment of Deutetrabenazine in Healthy Volunteers and Implications for Patients With Huntington Disease or Tardive Dyskinesia (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [P4.081] Tardive Dyskinesia Among Patients Using Antipsychotic Medications in Customary Clinical Care in the United States (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
- [S8.003] ARPEGGIO: A Placebo-controlled Trial of Oral Laquinimod in Primary Progressive Multiple Sclerosis (Platform Session 8, April 22, 2018, 3:30 - 5:30 p.m. PT)
- [P3.324] Pridopidine Treatment Recovers Gait Abnormalities and Rescues Impaired BDNF Expression in a Rett Syndrome Mouse Model (Poster Session 3, April 24, 2018, 11:30 - 7:00 p.m. PT)
- [P4.048] Loss of the Sigma-1 Receptor Disrupts Pridopidine-induced Gene Expression (Poster Session 4, April 25, 2018, 11:30 - 7:00 p.m. PT)
About COPAXONE® (glatiramer acetate injection)
COPAXONE® is indicated for the treatment of patients with relapsing forms of multiple sclerosis. Please click here for U.S. Full Prescribing Information: www.CopaxonePrescribingInformation.com. COPAXONE® is approved in more than 50 countries worldwide, including the United States, Russia, Canada, Mexico, Australia, Israel, and all European countries.
Important Safety Information about COPAXONE®
COPAXONE® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.
Approximately 16% of patients exposed to COPAXONE® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of patients exposed to COPAXONE® 40 mg per mL compared to none on placebo experienced a constellation of symptoms that may occur within minutes after injection and included at least 2 of the following: flushing, chest pain, palpitations, tachycardia, anxiety, dyspnea, throat constriction, and urticaria. In general, these symptoms have their onset several months after the initiation of treatment, although they may occur earlier, and a given patient may experience 1 or several episodes of these symptoms. Typically, the symptoms were transient and self-limited and did not require treatment; however, there have been reports of patients with similar symptoms who received emergency medical care.
Transient chest pain was noted in 13% of COPAXONE® 20 mg per mL patients compared to 6% of placebo patients, and approximately 2% of COPAXONE® 40 mg per mL patients compared to 1% on placebo. While some episodes of chest pain occurred in the context of the Post-Injection Reaction described above, many did not. The temporal relationship of this chest pain to an injection was not always known. The pain was usually transient, often unassociated with other symptoms, and appeared to have no clinical sequelae. Some patients experienced more than 1 such episode, and episodes usually began at least 1 month after the initiation of treatment.
At injection sites, localized lipoatrophy and, rarely, injection site skin necrosis may occur. Lipoatrophy may occur at various times after treatment onset (sometimes after several months) and is thought to be permanent. There is no known therapy for lipoatrophy.
Because COPAXONE® can modify immune response, it may interfere with immune functions. For example, treatment with COPAXONE® may interfere with recognition of foreign antigens in a way that would undermine the body’s tumor surveillance and its defenses against infection. There is no evidence that COPAXONE® does this, but there has not been a systematic evaluation of this risk.
In controlled studies of COPAXONE® 20 mg per mL, the most common adverse reactions with COPAXONE® vs placebo were injection site reactions (ISRs), such as erythema (43% vs 10%); vasodilatation (20% vs 5%); rash (19% vs 11%); dyspnea (14% vs 4%); and chest pain (13% vs 6%).
In a controlled study of COPAXONE® 40 mg per mL, the most common adverse reactions with COPAXONE® vs placebo were ISRs, such as erythema (22% vs 2%).
ISRs were one of the most common adverse reactions leading to discontinuation of COPAXONE®. ISRs, such as erythema, pain, pruritus, mass, edema, hypersensitivity, fibrosis, and atrophy, occurred at a higher rate with COPAXONE® than placebo.
About AUSTEDO® (deutetrabenazine)
AUSTEDO® is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of tardive dyskinesia in adults and for the treatment of chorea associated with Huntington’s disease. Safety and effectiveness in pediatric patients have not been established.
Important Safety Information
AUSTEDO® can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Anyone considering the use of AUSTEDO® must balance the risks of depression and suicidality with the clinical need for treatment of chorea. AUSTEDO® is contraindicated in patients with Huntington’s disease who are suicidal, or have untreated or inadequately treated depression.
AUSTEDO® is also contraindicated in: patients with hepatic impairment; patients taking reserpine or within 20 days of discontinuing reserpine; patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing MAOI therapy; and patients taking tetrabenazine (Xenazine®) or valbenazine (Ingrezza®).
AUSTEDO® may cause a worsening in mood, cognition, rigidity, and functional capacity in patients with Huntington’s disease. Tetrabenazine (a closely related VMAT2 inhibitor) causes an increase in the corrected QT (QTc) interval. A clinically relevant QT prolongation may occur in some patients treated with AUSTEDO® who are CYP2D6 poor metabolizers or are co-administered a strong CYP2D6 inhibitor or other drugs that are known to prolong QTc. Neuroleptic Malignant Syndrome has been observed in patients receiving tetrabenazine. AUSTEDO® may increase the risk of akathisia, agitation, and restlessness. AUSTEDO® may cause parkinsonism in patients with Huntington’s disease. Sedation is a common dose-limiting adverse reaction of AUSTEDO®.
The most common adverse reactions (4% of AUSTEDO®-treated patients and greater than placebo) in controlled clinical studies of patients with tardive dyskinesia were nasopharyngitis and insomnia. The most common adverse reactions (>8% of AUSTEDO®-treated patients and greater than placebo) in a controlled clinical study of patients with chorea associated with Huntington’s disease were somnolence, diarrhea, dry mouth, and fatigue.
Please click here for U.S. Full Prescribing Information, including Boxed Warning: austedo.com/hcp/pi.
Fremanezumab is a monoclonal antibody targeting the CGRP (calcitonin gene-related peptide) ligand, currently being investigated as a preventive treatment for migraine. With limited availability of preventive treatment options, fremanezumab represents a potential new option to address a significant unmet medical need.
Fremanezumab is also being investigated for the prevention of chronic and episodic cluster headache as part of the Phase III ENFORCE clinical research program, which has been granted fast track designation by the FDA. Fast track designation is intended to facilitate development and expedite review of drugs to treat serious or life-threatening conditions. Additionally, Teva has also recently initiated a fremanezumab Phase II clinical program for the treatment of post-traumatic headache disorder.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2017 were $22.4 billion. For more information, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Teva's innovative therapeutic solutions, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
- commercial success of the various Teva's innovative therapeutic solutions;
- challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals;
- our specialty medicines business, including: competition for our specialty products, especially COPAXONE®, our leading medicine, which faces competition from existing and potential additional generic versions and orally-administered alternatives; our ability to achieve expected results from investments in our product pipeline; competition from companies with greater resources and capabilities; and the effectiveness of our patents and other measures to protect our intellectual property rights;
- our substantially increased indebtedness and significantly decreased cash on hand, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;
- our business and operations in general, including: failure to effectively execute the recently announced restructuring plan; uncertainties related to, and failure to achieve, the potential benefits and success of our new senior management team and organizational structure; harm to our pipeline of future products due to the expected review of our R&D programs; our ability to develop and commercialize additional pharmaceutical products; potential additional adverse consequences following our resolution with the U.S. government of our FCPA investigation; compliance with sanctions and other trade control laws; manufacturing or quality control problems, which may damage our reputation for quality production and require costly remediation; interruptions in our supply chain; disruptions of our or third party information technology systems or breaches of our data security; the failure to recruit or retain key personnel; variations in intellectual property laws that may adversely affect our ability to manufacture our products; challenges associated with conducting business globally, including adverse effects of political or economic instability, major hostilities or terrorism; significant sales to a limited number of customers in our U.S. market; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets;
- compliance, regulatory and litigation matters, including: costs and delays resulting from the extensive governmental regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; governmental investigations into sales and marketing practices; potential liability for patent infringement; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks;
- other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;
and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2017, including in the section captioned “Risk Factors,” and in our other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov and www.tevapharm.com. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.